Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

doi:10.1186/ar2018

Download references

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

Serge D Steinfeld^*, Laure Tant, Gerd R Burmester, Nick KW Teoh, William A Wegener, David M Goldenberg and Olivier Pradier

* Corresponding author: Serge D Steinfeld ssteinfe@ulb.ac.be

Arthritis Research & Therapy 2006, 8:R129 doi:10.1186/ar2018

Include	Article citation and all cited references Cited references only Article citation only
Format	EndNote, Zotero or Papers Reference Manager Refworks BibTeX

Arthritis Research & Therapy

Viewing options

Associated material

Tools

Download references

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

Arthritis Research & Therapy

Viewing options

Associated material

Related literature

Cited by

Other articles by authors

Related articles/pages

Tools

Download references

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study